|
ProCure Treatment Center's mission is to increase the availability of proton therapy and provide access to the tens of thousands of cancer patients who could benefit from this advanced treatment. ProCure’s innovative turnkey solution for the design, construction, operation and maintenance of proton therapy facilities reduces the time, cost and effort necessary to create a facility.
ProCure Treatment Centers continues to play a pivotal role in the rapidly expanding field of proton therapy:
- Network of Proton Therapy Centers – Proton therapy is emerging outside of the academic medical community. ProCure Treatment Centers is working with community hospitals and local radiation oncology groups to bring proton therapy to more cancer patients across the country. On May 6, ProCure announced plans for a center in South Florida. Two other centers are planned for Illinois and Michigan, and one is under construction in Oklahoma City.
- World-Record Construction Timeline – The Oklahoma ProCure Treatment Center, which broke ground in April 2007, is scheduled to open in Summer 2009. It reached a major milestone with the arrival of the 220-ton cyclotron, putting the proton center on track to be completed in a world-record 27 months.
- First Proton Therapy Training Center in the World – The ProCure Training and Development Center (TDC), located in Bloomington, Ind., opened in March and is the first facility dedicated to proton therapy training. It offers clinical, technical, interpersonal and administrative training that pertains to all aspects of proton therapy treatment, giving employees “before-the-job” training. In April, the TDC announced a partnership with Ivy Tech Community College-Bloomington, to expand research and training programs for students at the school.
- Expanding Clinical Research – ProCure is partnering with the University of Pennsylvania, to expand research on the technology used in the delivery of proton therapy and to develop new protocols using protons to treat a wider range of cancer tumors. All centers in the ProCure network will participate in the clinical and other research.
- Committed Investors – On May 14, ProCure announced it received an additional $35 million round of equity funding from Oklahoma City-based McClendon Venture Company, LLC (MVC). MVC is owned by Aubrey K. McClendon, chairman and CEO of Chesapeake Energy Corporation, who said, “I have every reason to believe ProCure will become the gold standard for providing proton therapy to treat cancer in this country.” MVC has invested a total of $70 million in ProCure Treatment Centers.
|
